The global peripheral vascular devices market, valued at USD 4.7 billion in 2022, is projected to expand at a robust CAGR of 6.6%, reaching USD 8.9 billion by 2032, according to Future Market Insights ...

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

UK: A Mendelian randomization study published in the Journal of the American College of Cardiology identified elevated ...

Semaglutide, more commonly known as Ozempic, can do more than help with weight loss. A new clinical trial shows it helps ...

R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce ...

R3 Vascular Inc. announced that the first patient was enrolled in the company’s ELITE-BTK pivotal trial evaluating its Magn ...

• Antibiotics seem to reduce surgical site infections in people undergoing aortic or aortoiliac surgery. • Other interventions assessed appear to make little or no difference in reducing the incidence ...

R3 Vascular announced that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting ...

Efemoral Medical announced the presentation of long-term results from the initial 20 patients enrolled across four sites in ...

Pain in the back of your knee when walking? Learn the causes, symptoms, and best treatments to relieve discomfort and prevent ...

New research highlights how multimorbidity significantly worsens survival and physical function in patients with systemic ...